NEW DELHI: Sun Pharmaceutical Industries Ltd., India’s largest domestic drug maker by market capitalisation, plans to invest more than $280 million in the experimental psoriasis drug that it in-licensed from US-based Merck Sharp& Dohme (MSD) last month and hopes to commercialise globally by 2018, said industry consultants with direct knowledge of the matter.
This is part of Sun’s attempt to invest in a basket of promising innovative products in select therapies to grow beyond generics and add new revenue streams,
Help employers find you! Check out all the jobs and post your resume.
